Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EVICTION-2
2024-514758-65-00Phase 2Completed
- Sponsor
- ImCheck Therapeutics
- Start
- May 2022
- Modality
- Antibody-Based Therapeutics
- Countries
- 3
01
Overview
Phase 2, open-label trial of Ichnocim in metastatic colorectal adenocarcinoma (mCRC), Malignant ovarian neoplasm (OC), metastatic castration-resistant prostate cancer (mCRPC) and 2 more (2 arms), sponsored by ImCheck Therapeutics. Started May 2022; status: completed.
02
Drugs
Ichnocim
03
Conditions
metastatic colorectal adenocarcinoma (mCRC)Malignant ovarian neoplasm (OC)metastatic castration-resistant prostate cancer (mCRPC)pancreatic adenocarcinoma (PDAC)melanoma
Beyond the preview
Go deeper on 2024-514758-65-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514758-65-00.